Larimar Therapeutics Files 8-K

Ticker: LRMR · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1374690

Larimar Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form Type8-K
Filed DateOct 14, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC Filing, Corporate Disclosure

TL;DR

Larimar filed an 8-K on 10/14/25, standard stuff, no major news yet.

AI Summary

On October 14, 2025, Larimar Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information related to "Other Events" and "Financial Statements and Exhibits." No specific material events or financial details were disclosed in the provided text, but the filing itself is a standard corporate disclosure.

Why It Matters

This filing indicates Larimar Therapeutics is making a standard corporate disclosure to the SEC, which is a routine but necessary step for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine 8-K filing with no new material information disclosed in the provided text, indicating low immediate risk.

Key Numbers

  • 001-36510 — SEC File Number (Identifies the company's filing with the SEC)
  • 20-3857670 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — Registrant
  • October 14, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • Bala Cynwyd, Pennsylvania (location) — Principal Executive Offices
  • ZAFGEN, INC. (company) — Former Company Name

FAQ

What specific "Other Events" are being reported by Larimar Therapeutics, Inc. on October 14, 2025?

The provided text of the 8-K filing does not specify the details of the "Other Events" beyond listing it as an item information category.

Are there any new financial statements or exhibits being filed with this 8-K report?

The filing lists "Financial Statements and Exhibits" as an item information category, but the content of these exhibits is not detailed in the provided text.

What was Larimar Therapeutics, Inc.'s former company name?

Larimar Therapeutics, Inc. was formerly known as ZAFGEN, INC.

Where are Larimar Therapeutics, Inc.'s principal executive offices located?

The principal executive offices of Larimar Therapeutics, Inc. are located at Three Bala Plaza East, Bala Cynwyd, Pennsylvania, 19004.

What is the SEC file number for Larimar Therapeutics, Inc.?

The SEC file number for Larimar Therapeutics, Inc. is 001-36510.

Filing Stats: 462 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-10-14 07:00:46

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market

Filing Documents

01 Other Events

Item 8.01 Other Events. On October 14, 2025, Larimar Therapeutics, Inc. (the "Company") posted on its website an updated slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Larimar Therapeutics, Inc. Corporate Presentation, dated October 14, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: October 14, 2025 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.